RADICAVA ORS® (edaravone) offers patients an oral option that's formulated to fit their life's routines.1
FDA-APPROVED & AVAILABLE
RADICAVA® (edaravone) helps slow the loss of physical function in patients with ALS
For Their Moments
Big and Small
Of the 2000+
US HCPs that have prescribed RADICAVA® since August 2017, 1400+ are general neurologists2,a (see footnote)
patients treated with
RADICAVA® for 1.2 million+ days of therapy in the US as of
February 20232,a,b (see footnote)
79% of patients
starting RADICAVA® from
June-November 2022 stayed on treatment for 3 months or
more2,c (see footnote)
Proven Efficacy Now
in Oral Form
33% less change in ALSFRS-R from baseline vs placebo at 24 weeks.1,3
Flexible Administration with Oral Dosing
5 mL dose administered in minutes, not hours, as well as an IV option.1
Starting Patients & Cost Support Options
Review steps to beginning or transitioning to oral treatment that can fit into their daily routine.1
The JourneyMate Support Program™ helps to give patients understanding, answers, and resources to supplement what their doctor provides. Experienced program team members are trained to address patient educational needs and provide them with personalized answers and resources for living with ALS.
The JourneyMate Support Program™ offers educational support and resources for patients who are considering or have already been prescribed a Mitsubishi Tanabe Pharma America, Inc. (MTPA) product. An ALS Clinical Educator is an educational resource for patients who have been prescribed an MTPA product. An ALS Clinical Educator is provided by MTPA and VMS and is not affiliated with or provided by a doctor. An ALS Clinical Educator does not provide medical advice. The program does not provide medical advice and does not take the place of a patient's doctor. All questions about a condition, diagnosis, or treatment should be referred to the patient's doctor. If a patient has a medical emergency, they should call 911. Adverse events or product complaints should be reported by calling 1-888-292-0058.
ALS=Amyotrophic lateral sclerosis.
aBased on RADICAVA ORS® and RADICAVA® IV prescriptions submitted in the US as of February 2023. Not independently verified. Return to content
bDays of therapy based on number of RADICAVA ORS® and RADICAVA® IV cartons sold as of February 2023. Each carton represents a day’s supply of therapy. Return to content
cPatients who started RADICAVA ORS® or RADICAVA® IV between June 2022 and November 2022 and continued for 3 months or more through February 2023. Return to content
References: 1. RADICAVA and RADICAVA ORS Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2022. 2. Data on file. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc. 3. Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512.